BibTex format
@article{Armstrong-James:2020:10.1183/13993003.02554-2020,
author = {Armstrong-James, D and Youngs, J and Bicanic, T and Abdolrasouli, A and Denning, DW and Johnson, E and Mehra, V and Pagliuca, T and Patel, B and Rhodes, J and Schelenz, S and Shah, A and van, de Veerdonk FL and Verweij, PE and White, PL and Fisher, MC},
doi = {10.1183/13993003.02554-2020},
journal = {European Respiratory Journal},
pages = {1--10},
title = {Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA)},
url = {http://dx.doi.org/10.1183/13993003.02554-2020},
volume = {56},
year = {2020}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections.The SARS-CoV-2 (COVID-19) virus causes a wide spectrum of disease in healthy individuals as well as those with common comorbidities [1]. Severe COVID-19 is characterised acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.Fungal disease consistent with invasive aspergillosis (IA) has been observed with other severe Coronaviruses such as Severe Acute Respiratory Syndrome (SARS-CoV-2003) [4, 5] and Middle East Respiratory Syndrome (MERS-CoV) [6]. From the outset of the COVID-19 pandemic, there were warning signs of secondary invasive fungal infection; Aspergillus flavus was isolated from the respiratory tract from one of 99 patients in the first COVID-19 cohort from Wuhan to be reported in any detail [2] and Aspergillus spp. were isolated from 2/52 (3.8%) of a subsequent cohort of critically unwell patients from this region [7]. More recently, retrospective case series from Belgium [8], France [9], The Netherlands [10] and Germany [11] have reported evidence of CAPA in an alarming 20–35% of mechanically ventilated patients.
AU - Armstrong-James,D
AU - Youngs,J
AU - Bicanic,T
AU - Abdolrasouli,A
AU - Denning,DW
AU - Johnson,E
AU - Mehra,V
AU - Pagliuca,T
AU - Patel,B
AU - Rhodes,J
AU - Schelenz,S
AU - Shah,A
AU - van,de Veerdonk FL
AU - Verweij,PE
AU - White,PL
AU - Fisher,MC
DO - 10.1183/13993003.02554-2020
EP - 10
PY - 2020///
SN - 0903-1936
SP - 1
TI - Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA)
T2 - European Respiratory Journal
UR - http://dx.doi.org/10.1183/13993003.02554-2020
UR - https://www.ncbi.nlm.nih.gov/pubmed/32703771
UR - https://erj.ersjournals.com/content/56/4/2002554.article-info
UR - http://hdl.handle.net/10044/1/81083
VL - 56
ER -
